{"denoms":[{"counts":[{"groupId":"BG000","value":"369"},{"groupId":"BG001","value":"368"},{"groupId":"BG002","value":"737"}],"units":"Participants"}],"groups":[{"description":"Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity up to 77.5 months. After completion of treatment, participants entered follow-up phase and were not started on subsequent anti-myeloma therapy without confirmed disease progression (assessed by the International Myeloma Working Group \\[IMWG\\] criteria).","id":"BG000","title":"Lenalidomide + Dexamethasone (Rd)"},{"description":"Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity up to 77.3 months. After implementation of Amendment 8, participants who were ongoing with daratumumab IV treatment were given an option to switch to daratumumab subcutaneous (SC) injection on Day 1 of any cycle, as per investigator's discretion. After completion of treatment, participants entered follow-up phase and were not started on subsequent anti-myeloma therapy without confirmed disease progression (assessed by IMWG criteria).","id":"BG001","title":"Daratumumab + Lenalidomide + Dexamethasone (DRd)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.66","value":"74.2"},{"groupId":"BG001","spread":"5.44","value":"74.0"},{"groupId":"BG002","spread":"5.55","value":"74.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"174"},{"groupId":"BG001","value":"179"},{"groupId":"BG002","value":"353"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"195"},{"groupId":"BG001","value":"189"},{"groupId":"BG002","value":"384"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"23"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"352"},{"groupId":"BG001","value":"347"},{"groupId":"BG002","value":"699"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"339"},{"groupId":"BG001","value":"336"},{"groupId":"BG002","value":"675"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"28"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"13"}],"title":"Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"35"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"14"}]}],"title":"Austria"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}]}],"title":"Belgium"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"16"}]}],"title":"Denmark"},{"categories":[{"measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"312"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"35"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]}],"title":"Ireland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}]}],"title":"Israel"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"22"}]}],"title":"Sweden"},{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"67"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"151"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"201"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"163"},{"groupId":"BG002","value":"319"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"217"}]}],"title":"Stage III"}],"description":"The International Staging System (ISS) consists of following 3 stages - Stage I: serum beta2-microglobulin less than (\\<) 3.5 milligrams per liter (mg/L) and albumin greater than or equal to (\\>=) 3.5 grams per 100 Milliliter (g/100 mL); Stage II: neither stage I nor stage III and Stage III: serum beta2-microglobulin \\>= 5.5 mg/L.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage of Disease (ISS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.4","value":"1.3"},{"groupId":"BG001","spread":"1.5","value":"1.4"},{"groupId":"BG002","spread":"1.5","value":"1.3"}]}]}],"description":"Time from MM diagnosis is the time from diagnosis of multiple myeloma to randomization in each treatment group.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time from Multiple Myeloma (MM) diagnosis","unitOfMeasure":"Months"}]}